Nicholas Jon Virca Net Worth

Mr. Nicholas Jon Virca biography

Nicholas Jon Virca is the Pres & CEO at Inhibitor Therapeutics.

What is the salary of Mr Virca?

As the Pres & CEO of Inhibitor Therapeutics, the total compensation of Mr Virca at Inhibitor Therapeutics is $144,684. There are no executives at Inhibitor Therapeutics getting paid more.

How old is Mr Virca?

Mr Virca is 75, he's been the Pres & CEO of Inhibitor Therapeutics since . There are no older and 1 younger executives at Inhibitor Therapeutics.

What's Mr Virca's mailing address?

Nicholas's mailing address filed with the SEC is 449 SOUTH 12TH STREET, UNIT 1705, , TAMPA, FL, 33602.

Insiders trading at Inhibitor Therapeutics

Over the last 5 years, insiders at Inhibitor Therapeutics have traded over $0 worth of Inhibitor Therapeutics stock and bought 13,500 units worth $945 . The most active insiders traders include James A Mcnulty, W. Mark Watson, and Samuel P Jr Sears. On average, Inhibitor Therapeutics executives and independent directors trade stock every 0 days with the average trade being worth of $1,080. The most recent stock trade was executed by Garrison J. Hasara on 2 December 2019, trading 13,500 units of INTI stock currently worth $945.

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Inhibitor Therapeutics executives and stock owners

Inhibitor Therapeutics executives and other stock owners filed with the SEC include:

• Nicholas Jon Virca,
  Pres & CEO
• Garrison J. Hasara CPA, CPA,
  CFO, Treasurer, Corp. Sec. & Chief Compliance Officer
• Pharma Ventures Pty Ltd May...,
  
• Debra Peattie,
  Director
• Robert Daniel Martin,
  Director
• Garrison J. Hasara,
  CFO and Treasurer
• Richard Dana Ono,
  Director
• Nicholas J Virca,
  President and CEO
• W. Mark Watson,
  Director
• Michelle Yanez,
  Director
• James A Mcnulty,
  CHIEF FINANCIAL OFFICER
• Ronald E Ronald E Osman Irr...,
  
• Samuel P Jr Sears,
  Director
• Michael Allen Jerman,
  Director